Novartis Institutes of Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, USA.
Cytometry B Clin Cytom. 2021 Jan;100(1):42-51. doi: 10.1002/cyto.b.21949. Epub 2020 Sep 17.
The current consensus recommendation papers dealing with the unique requirements for the analytical validation of assays performed by flow cytometry address the validation of sensitivity (both analytical and functional) only in general terms. In this paper, a detailed approach for designing and validating the sensitivity of rare event methods is described. The impact of panel design and optimization on the lower limit of quantification (LLOQ) and suggestions for reporting data near, or below, the LLOQ are addressed. This paper serves to provide best practices for the development, optimization, and analytical validation of flow cytometric assays designed to assess rare events. Note that this paper does not discuss clinical sensitivity validation, which addresses the positive and negative predictive value of the test result.
目前,涉及流式细胞术分析验证独特要求的共识推荐文件仅一般性地讨论了分析灵敏度(包括分析灵敏度和功能灵敏度)的验证。本文详细介绍了设计和验证稀有事件方法灵敏度的方法。本文还讨论了面板设计和优化对定量下限(LLOQ)的影响,以及关于报告接近或低于LLOQ 数据的建议。本文旨在为旨在评估稀有事件的流式细胞术检测的开发、优化和分析验证提供最佳实践。请注意,本文不讨论临床灵敏度验证,后者涉及检测结果的阳性和阴性预测值。